How Will the Idelalisib + Ofatumumab Trial Affect Planning in CLL

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about How the Idelalisib+Ofatumumab Trial Affect Planning in CLL